How to Get Addyi (Flibanserin) in Maryland

What Is Flibanserin and Who Is It For?

Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist approved by the FDA in August 2015 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not a hormonal therapy. The drug modulates serotonin, dopamine, and norepinephrine activity in the prefrontal cortex, and clinical data from the BEGONIA trial (N=1,087) showed statistically significant increases in satisfying sexual events (SSEs) compared to placebo over 24 weeks.

HSDD affects an estimated 8% to 10% of women aged 20 to 49, according to prevalence data published in Obstetrics & Gynecology. The condition is distinct from low desire caused by relationship conflict, medication side effects, or psychiatric illness. A proper HSDD diagnosis requires that the reduced desire causes marked personal distress and is not better explained by another medical or psychological condition, per ISSWSH diagnostic criteria.

Maryland residents who meet these criteria have several pathways to a prescription, including telehealth platforms that operate under Maryland's telemedicine regulations.

Maryland Telehealth Prescribing Rules for Addyi

Maryland fully authorizes telehealth prescribing for controlled and non-controlled medications under COMAR 10.32.05. The Maryland Board of Physicians requires that a valid provider-patient relationship be established before any prescription is issued, but this relationship can be formed through a synchronous audio-video visit. No in-person visit is required first.

For flibanserin specifically, the prescribing clinician must be enrolled in the Addyi REMS program, a requirement from the FDA that applies in all 50 states. The REMS certification involves completing a knowledge assessment confirming the prescriber understands the alcohol interaction risk, contraindicated medications (moderate or strong CYP3A4 inhibitors, per the FDA label), and the need for hepatic function assessment before initiation.

Telehealth platforms operating in Maryland typically assign a licensed prescriber (MD, DO, NP, or PA) who holds an active Maryland license. The clinical intake covers menstrual status, current medications, alcohol use, and liver function. If a patient has had a comprehensive metabolic panel within the past 6 months, many providers accept those results without ordering repeat labs.

Who Can Prescribe Addyi in Maryland?

Any clinician with independent or supervised prescriptive authority under Maryland law may prescribe flibanserin, provided they hold REMS certification. That includes physicians (MD and DO), nurse practitioners, and physician assistants.

Maryland NPs gained full practice authority in 2015 after completing a supervised practice period. PAs prescribe under a written delegation agreement with a supervising physician, per Maryland Health Occupations Article §15-301. Both NPs and PAs routinely prescribe flibanserin through telehealth platforms in Maryland. There is no specialty restriction. Primary care providers, OB-GYNs, psychiatrists, and sexual medicine specialists can all prescribe the medication after REMS enrollment.

The American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 756 notes that all clinicians who treat premenopausal women should be prepared to screen for sexual dysfunction, including HSDD. This guidance supports the broad prescriber eligibility model used in Maryland.

What Labs Are Required Before Starting Addyi?

The FDA label recommends evaluating hepatic function before prescribing flibanserin because the drug is extensively metabolized by CYP3A4 in the liver. Flibanserin is contraindicated in patients with hepatic impairment of any degree. A standard comprehensive metabolic panel (CMP) provides the necessary ALT, AST, and bilirubin values.

Most telehealth providers also order or request a recent thyroid panel (TSH), because hypothyroidism is a common reversible cause of low desire that should be excluded before attributing symptoms to HSDD, per Endocrine Society guidelines. Checking a prolactin level may be warranted in women reporting galactorrhea, as hyperprolactinemia independently suppresses libido.

A medication reconciliation is equally important. Flibanserin must not be combined with moderate or strong CYP3A4 inhibitors, including fluconazole, ketoconazole, and certain HIV protease inhibitors. The FDA drug interaction data show that co-administration with fluconazole increased flibanserin AUC by approximately 7-fold, raising the risk of severe hypotension and syncope.

Labs are typically completed at a Quest, Labcorp, or local Maryland hospital outpatient lab within 2 to 3 business days. Some telehealth platforms provide mobile phlebotomy for an additional fee.

Maryland Medicaid Coverage and Prior Authorization

Maryland Medicaid covers brand-name Addyi with prior authorization (PA) for premenopausal women diagnosed with HSDD. The PA process is administered through the Maryland Department of Health's Pharmacy Program.

Documentation required for a successful PA submission generally includes:

• A confirmed HSDD diagnosis using standardized screening tools such as the Decreased Sexual Desire Screener (DSDS)
• Evidence that the low desire is acquired and generalized, not situational
• Lab results confirming normal hepatic function
• A medication list demonstrating no contraindicated drug interactions
• Documentation that non-pharmacologic options (e.g., therapy or lifestyle modification) have been considered

PA turnaround in Maryland typically takes 24 to 72 hours for standard requests. Urgent requests, though uncommon for this indication, may be processed within 24 hours. If the initial PA is denied, Maryland Medicaid allows a formal appeal under COMAR 10.09.03.

For patients with commercial insurance, coverage varies by plan. Many insurers classify Addyi as a non-preferred brand, which may result in higher copays or step therapy requirements. The manufacturer, Sprout Pharmaceuticals, has periodically offered savings cards that reduce out-of-pocket costs for commercially insured patients, though availability of these programs changes. The brand-name cash price averages approximately $400 to $500 for a 30-day supply at Maryland retail pharmacies.

503A Compounding Pharmacies in Maryland

Maryland-licensed 503A compounding pharmacies may prepare flibanserin formulations based on a patient-specific prescription. These pharmacies are regulated by the Maryland Board of Pharmacy and must comply with USP 795 standards for non-sterile compounding.

A compounded formulation may cost less than brand-name Addyi. Cash prices at 503A pharmacies for a 30-day supply of compounded flibanserin typically range from $50 to $150, depending on the pharmacy and formulation. The tradeoff is that compounded medications are not FDA-approved finished products and do not undergo the same batch-level testing as commercial drugs. The FDA has outlined the distinction between 503A and 503B compounding in its regulatory framework.

To fill a compounded flibanserin prescription in Maryland, the prescriber must write a patient-specific prescription. 503A pharmacies cannot compound and distribute without an individual prescription, unlike 503B outsourcing facilities, which can prepare stock under different rules.

Some 503A pharmacies in Maryland ship statewide. Patients in rural areas of western Maryland or the Eastern Shore can receive compounded flibanserin by mail, provided the pharmacy holds the appropriate Maryland shipping license.

How Long Until You Receive Addyi in Maryland?

The timeline from initial consultation to medication in hand typically spans 5 to 10 business days. Here is a realistic breakdown.

The telehealth consultation itself takes 20 to 40 minutes. If lab work is ordered the same day, results return in 1 to 3 business days from major reference labs. The prescriber reviews results and submits the prescription within 1 to 2 business days. Pharmacy dispensing and shipping add 2 to 4 business days. Brand-name Addyi is often dispensed through specialty or mail-order pharmacies that require signature upon delivery.

If prior authorization is needed for Medicaid, add 1 to 3 business days for the PA decision. Patients using a 503A compounding pharmacy may see slightly longer compounding times (1 to 3 business days for preparation), but shipping within Maryland is typically overnight or two-day.

Patients who already have recent lab work on file can reduce the total timeline to as few as 3 to 5 business days.

Transferring an Addyi Prescription to Maryland

If you already hold an active flibanserin prescription from another state, a Maryland-licensed pharmacy can accept the transfer, provided the original pharmacy and the receiving pharmacy agree to the transfer under standard DEA transfer regulations. Flibanserin is not a controlled substance, which simplifies the transfer process.

The receiving pharmacist will verify that the prescriber is REMS-certified and that the prescription has remaining refills. Maryland does not impose additional state-level restrictions on transferring non-controlled prescriptions from out-of-state pharmacies, per Maryland Health-General Article §21-225.

If the original prescription has no refills remaining, a new Maryland-licensed provider must write a new prescription. Telehealth makes this straightforward. Most platforms can complete a new clinical evaluation and issue a prescription within 48 hours.

Alcohol and Safety: The Boxed Warning

The FDA's boxed warning on Addyi addresses the risk of severe hypotension and syncope when flibanserin is taken with alcohol. In a pharmacokinetic study, co-administration of flibanserin 100 mg with 0.4 g/kg ethanol in fed subjects resulted in a 4-fold increase in the incidence of clinically significant hypotension or syncope compared with flibanserin alone.

The REMS program originally required prescribers to counsel patients on this interaction and patients to sign a patient-provider agreement form. The FDA modified the REMS in 2019, removing the pharmacy certification and dispensing requirements while retaining the prescriber certification element. The practical advice remains the same: patients should avoid alcohol on any day they take flibanserin.

Post-marketing safety data published in the Journal of Clinical Pharmacology confirmed that the hypotension risk is dose-dependent and that taking flibanserin at bedtime (as labeled) reduces the clinical significance of any blood pressure reduction, since the patient is already supine.

Clinical Efficacy: What the Trials Show

Three key phase III trials (VIOLET, DAISY, and BEGONIA) enrolled a combined total of approximately 3,500 premenopausal women with HSDD. Across all three, flibanserin 100 mg at bedtime produced a statistically significant increase of 0.5 to 1.0 additional SSEs per month compared with placebo (P<0.01). The drug also significantly improved scores on the Female Sexual Function Index (FSFI) desire domain and reduced distress as measured by the Female Sexual Distress Scale-Revised (FSDS-R).

"The benefit of flibanserin on sexual desire and related distress is modest but clinically meaningful for the individual patient," noted Dr. Sheryl Kingsberg, a lead investigator on the BEGONIA trial and professor of reproductive biology at Case Western Reserve University, in a 2014 publication.

Response typically takes 4 to 8 weeks. The FDA label recommends discontinuing flibanserin after 8 weeks if the patient reports no improvement in desire or distress. For women who do respond, long-term extension data published in the Journal of Sexual Medicine showed that benefits persisted over 12 months of continued treatment without tachyphylaxis.

The most common adverse effects in trials were dizziness (11.4% vs. 2.2% placebo), somnolence (11.2% vs. 3.1%), and nausea (10.4% vs. 3.9%), based on pooled safety data reported to the FDA.

Maryland-Specific Resources for HSDD Evaluation

The Johns Hopkins Women's Health Center and the University of Maryland Medical Center both offer sexual medicine programs where clinicians evaluate HSDD and can prescribe flibanserin. These academic centers may be helpful for patients whose cases are complicated by psychiatric comorbidities, prior treatment failures, or concurrent medications that require careful interaction screening.

For patients who prefer a private practice setting, the ISSWSH provider directory lists board-certified sexual medicine specialists in Maryland. The International Society for the Study of Women's Sexual Health maintains this directory as a resource for locating clinicians trained in female sexual dysfunction, per their 2016 process of care recommendations.

Maryland's proximity to Washington, D.C. also expands access. Some D.C.-based sexual medicine specialists hold dual licensure in Maryland and the District, allowing Maryland residents to see them without geographic barriers.